Damora Therapeutics presents DMR-001 development plan, targets clinical proof-of-concept readouts from mid-2027
DMRA•Damora Therapeutics expects two clinical proof-of-concept readouts for DMR-001 beginning in mid-2027. It reported approximately $529 million in cash, cash equivalents and marketable securities at September 30, 2026, which it expects to fund operations into the second half of 2029.
1. Clinical development plan
Damora Therapeutics said its Phase 1/1b CLARITY-101 trial of DMR-001 is enrolling, with two clinical proof-of-concept readouts expected beginning in mid-2027. Trial results could support Phase 3 initiation as early as mid-2028, subject to data and regulatory feedback. The company plans first regulatory submissions for DMR-002 in the fourth quarter of 2026 and DMR-003 in 2027.
2. Cash position
Cash, cash equivalents and marketable securities totaled approximately $529 million at September 30, 2026, which the company said would fund operations into the second half of 2029.
